


COVID-19

Immunity Assessment Test

Neutralizing Antibody Range



Test Name	Result	Reference Range															
Neutralizing Antibody Test	High Positive	<table border="1"> <thead> <tr> <th>Range</th> <th>Titer (U/ml)</th> <th>Estimated Immunity</th> </tr> </thead> <tbody> <tr> <td>Negative</td> <td>Not Detected</td> <td>Not Determined*</td> </tr> <tr> <td>Low</td> <td><1500</td> <td>50 - 75%</td> </tr> <tr> <td>Medium</td> <td>1500-5000</td> <td>>75 - 90%</td> </tr> <tr> <td>High</td> <td>>5000</td> <td>>90%</td> </tr> </tbody> </table>	Range	Titer (U/ml)	Estimated Immunity	Negative	Not Detected	Not Determined*	Low	<1500	50 - 75%	Medium	1500-5000	>75 - 90%	High	>5000	>90%
Range	Titer (U/ml)	Estimated Immunity															
Negative	Not Detected	Not Determined*															
Low	<1500	50 - 75%															
Medium	1500-5000	>75 - 90%															
High	>5000	>90%															

Anti-SARS-CoV-2 Competitive Viral Neutralization Test (cVNT): A Blocking Enzyme-Linked Immunosorbent Assay (ELISA) intended for the semi-quantitative detection of total neutralizing antibodies to SARS-CoV-2¹. The test provides semi-quantitative results (negative, low positive, medium positive, high positive) based on a standard curve of control samples and established thresholds.

A Neutralizing Antibody (NAb) is an antibody that is responsible for defending cells from pathogens, which are microorganisms that cause infection. They are produced naturally by the body as part of its immune response, and their production is triggered by both infections and vaccinations against infections². SARS-CoV-2 Neutralizing Antibodies have been shown to be highly predictive of immune protection from symptomatic SARS-CoV-2 infection^{3,4}.

*Individuals with prior COVID-19 immune response from vaccination or infection may still have significant immunity in the absence of detectable neutralizing antibodies.^{3,4}

Ordering Physician	Specimen Information	Patient Information
Dr. John Smith	Specimen Type: Blood	Name: John Q. Sample
NPI # 184756325	Accession #: P000001139	Date of Birth: 01 / 14 / 2021
2900 N. Sepulveda Blvd	Collection Date: 04 / 05 / 2021	Patient ID/MRN: 483474
Manhattan Beach, CA 90266	Accession Date: 04 / 06 / 2021	Gender: Male
CPT Codes: 86409, 86769	Report Date: 04 / 08 / 2021	Requisition #: 2948376

Disclaimer: The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding course of medical treatment must be made only after consulting with a licensed physician or other licensed healthcare professional and should consider each patient's medical history. Validation was performed by DxTerity Diagnostics Inc. CLIA # 05D2054007 on an open automated ELISA system.

- References:**
1. Tan C.W. et al A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE-2-spike protein-protein interaction. Nat. Biotechnol. (2020)
 2. <https://www.news-medical.net/health/What-are-Neutralizing-Antibodies.aspx>
 3. Khoury DS, Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection, Nat Med (2021). <https://doi.org/10.1038/s41591-021-01377-8>
 4. DxTerity White Paper – SARS-CoV-2 Neutralizing Antibody Levels Provide Estimate of COVID-19 Protection Following Vaccination or Infection. DxTerity Data on File